ProMIS Neurosciences Net debt/EBITDA
Was ist das Net debt/EBITDA von ProMIS Neurosciences?
Net debt/EBITDA von ProMIS Neurosciences, Inc. ist 4.30
Was ist die Definition von Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA von Unternehmen in Health Care Sektor auf OTC im Vergleich zu ProMIS Neurosciences
Was macht ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Unternehmen mit net debt/ebitda ähnlich ProMIS Neurosciences
- PHX Minerals Inc hat Net debt/EBITDA von 4.28
- ViewRay hat Net debt/EBITDA von 4.28
- Neometals Ltd hat Net debt/EBITDA von 4.28
- UPM-Kymmene Oyj hat Net debt/EBITDA von 4.28
- Mexco Corp hat Net debt/EBITDA von 4.28
- Maya Gold and Silver hat Net debt/EBITDA von 4.30
- ProMIS Neurosciences hat Net debt/EBITDA von 4.30
- HelloFresh SE hat Net debt/EBITDA von 4.30
- Littelfuse hat Net debt/EBITDA von 4.30
- Zhengzhou Coal Mining Machinery hat Net debt/EBITDA von 4.31
- GCL-Poly hat Net debt/EBITDA von 4.31
- Enlivex Therapeutics hat Net debt/EBITDA von 4.31
- Sensorion SAS hat Net debt/EBITDA von 4.31